Chinese Journal of Pharmacovigilance ›› 2023, Vol. 20 ›› Issue (12): 1346-1350.
DOI: 10.19803/j.1672-8629.20230541

Previous Articles     Next Articles

Uncertainty evaluation on the determination of norvancomycin in human cerebrospinal fluid by UPLC-MS/MS

WANG Jiaqing1, WANG Qi2△, ZHANG Dongjie3, MEI Shenghui3,*, NING Xiao2#   

  1. 1Clinical Trial Center, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China;
    2Institute for control of Chinese traditional medicine and ethnic medicine, National Institutes for Food and Drug Control, Beijing 100050, China;
    3Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China;
    4Institute for Food and Cosmetics Testing, National Institutes for Food and Drug Control, Beijing 100050, China
  • Received:2023-09-01 Online:2023-12-15 Published:2023-12-15

Abstract: Objective To evaluate the uncertainty in norvancomycin (NVCM) determination in human cerebrospinal by UPLC-MS/MS. Methods The whole process during the NVCM determination was analyzed and the uncertainty sources were established, then the combined and expanded uncertainty were also evaluated. Results The expanded uncertainty with low (3 mg·L-1) and high (300 mg·L-1) levels of NVCM (P=95%, k=2) were 1.18 mg·L-1 and 70.97 mg·L-1, respectively. Conclusion The uncertainty in NVCM determination in human cerebrospinal by UPLC-MS/MS was mainly caused by curve fitting, repeatability and recovery for low concentrations and repeatability, matrix effect and recovery for high concentrations. The method for determining the content of NVCM in cerebrospinal fluid established by our research institute provides an effective regulatory means for the safety and effectiveness of the drug’s use.

Key words: NVCM, human cerebrospinal fluid, UPLC-MS/MS, UNcertainty evaluation, content, safety

CLC Number: